# A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.

> **NCT07339514** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ExoRNA Bioscience** · enrollment: 27 (estimated)

## Conditions studied

- Huntington Disease

## Interventions

- **DRUG:** ER2001 intravenous injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07339514
- **Lead sponsor:** ExoRNA Bioscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-02-11
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-05-30
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07339514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07339514, "A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease.". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07339514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*